Clinical Trials Logo

Thymidine Kinase 2 Deficiency clinical trials

View clinical trials related to Thymidine Kinase 2 Deficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT05017818 Completed - Clinical trials for Thymidine Kinase 2 Deficiency

A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

Start date: July 23, 2021
Phase:
Study type: Observational

This is a multicenter, multinational, retrospective chart-review study to evaluate survival in patients with Thymidine Kinase 2 deficiency (TK2d).

NCT ID: NCT04581733 Withdrawn - Clinical trials for Thymidine Kinase 2 Deficiency

A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)

Start date: September 30, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, prospective, single-arm, multicenter, open-label treatment study of the efficacy and safety of MT1621 in pediatric and adolescent patients with thymidine kinase 2 deficiency (TK2d). In order to be eligible for this study, participants must have genetic confirmation of TK2d and must not have ever received MT1621 or nucleos(t)ides before entering the study.

NCT ID: NCT03845712 Active, not recruiting - Clinical trials for Thymidine Kinase 2 Deficiency

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

Continuation
Start date: July 5, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 [NCT03701568] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.

NCT ID: NCT03639701 Active, not recruiting - Clinical trials for Thymidine Kinase 2 Deficiency

Treatment of TK2 Deficiency With Thymidine and Deoxycytidine

Start date: May 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with confirmed mitochondrial DNA depletion syndrome 2 (thymidine kinase 2 [TK2] deficiency) have reduced levels of nucleotides (deoxythymidine monophosphate and deoxycytidine monophosphate) for mitochondrial DNA synthesis. This results in mitochondrial DNA depletion syndrome (i.e less number of functional mitochondrial DNA). Patients with confirmed TK2 deficiency will be treated with open label deoxythymidine (dThd) and deoxycytidine (dCyt), which are nucleotide precursors, with the expectation that the cells could make additional mitochondrial DNA. This in turn may help reduce the clinical symptoms.